Insmed (INSM) Gets Faster FDA Review. Can Its Lung Drug Reach More Patients?

insidermonkey.com · 2026-09-28

Insmed Incorporated (NASDAQ:INSM) announced on September 21 that the FDA accepted its supplemental application for ARIKAYCE and granted priority review, setting January 28, 2027, as the target decision...

Read the full story at insidermonkey.com →